Leopardlike PET Pattern and Sarcoidlike Reaction - Scorecard - MDSpire

Leopardlike PET Pattern and Sarcoidlike Reaction

A rare but often favorable immune-related adverse event associated with immune checkpoint inhibitors can mimic cancer progression on imaging and typically resolves with conservative management.

  • By

  • Kathryn Wighton

  • January 9, 2026

  • 3 min

Share

Clinical Scorecard: Leopardlike PET Pattern and Sarcoidlike Reaction

At a Glance

CategoryDetail
ConditionDrug-induced sarcoidosislike reaction (SLR)
Key MechanismsImmune checkpoint inhibitor therapy leading to systemic granulomatous response
Target PopulationPatients receiving immune checkpoint inhibitors, particularly those with a history of malignancies
Care SettingOncology and Internal Medicine

Key Highlights

  • Distinctive leopardlike pattern of hypermetabolic muscle lesions on PET/CT
  • SLRs can mimic malignancy but are often associated with tumor control
  • Approximately 4% prevalence among patients treated with immune checkpoint inhibitors
  • More than 90% of lesions improve or resolve regardless of corticosteroid use
  • Biopsy is crucial to differentiate SLR from true tumor progression

Guideline-Based Recommendations

Diagnosis

  • Use FDG-PET/CT to identify hypermetabolic lesions
  • Perform muscle and skin biopsies to confirm diagnosis

Management

  • Consider conservative management with local wound care
  • Corticosteroids may not be necessary for resolution

Monitoring & Follow-up

  • Regular imaging to assess lesion resolution
  • Monitor clinical symptoms for improvement

Risks

  • Misdiagnosis as tumor progression can lead to inappropriate treatment

Patient & Prescribing Data

Patients with a history of squamous cell carcinomas receiving durvalumab

Durvalumab was stopped; local wound care led to complete resolution within 3 months

Clinical Best Practices

  • Emphasize the importance of biopsy in ambiguous cases
  • Educate patients about the potential for SLR as an immune-related adverse event
  • Monitor for asymptomatic cases, as many may go unrecognized

Related Resources & Content

Original Source(s)

Leopardlike PET Pattern and Sarcoidlike Reaction

  • by Kathryn Wighton

  • January 9, 2026

Related Content

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

PET/CT and MRI Model May Help Stratify Prostate Cancer Risk

Retrospective multicenter radiomics study showed moderate to high discrimination in two small external cohorts

Symposium on Magnetic Resonance in Radiation Therapy, 13th Annual

This internationally-recognized symposium is the premier global platform for showcasing the fast advancement of technology and the rapid integration of MRI into radiotherapy applications into the field of radiation oncology.

  • by

  • July 9, 2026

  • 1 min